Bioresorbable coronary scaffolds: A novel device-based solution in search of its clinical need

European Heart Journal

Volumn 35, Issue 12, 2014, Pages 753-757

  Barbato, Emanuele ^a   Wijns, William ^a  

^a CARDIOVASCULAR CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; EVEROLIMUS; RAPAMYCIN; TUBULIN MODULATOR;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; BALLOON DILATATION; BARE METAL STENT; BIORESORBABLE CORONARY SCAFFOLD; BIORESORBABLE SCAFFOLD; CHRONIC INFLAMMATION; CORONARY ARTERY OCCLUSION; DRUG ELUTING STENT; EMBOLISM; EVEROLIMUS ELUTING BIORESORBABLE VASCULAR SCAFFOLD; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; ISCHEMIC HEART DISEASE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SUDDEN DEATH; THROMBUS ASPIRATION; ANALOGS AND DERIVATIVES; FEMALE; MALE; MYOCARDIAL INFARCTION; TISSUE SCAFFOLD;

DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; SIROLIMUS; TISSUE SCAFFOLDS; TUBULIN MODULATORS;

EID: 84896985952     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu005     Document Type: Review

References (17)

1. Iqbal J, Onuma Y, Ormiston J, Abizaid A, Waksman R, Serruys P. Bioresorbable coronary scaffolds:a novel device-based solutioninsearchofits clinical need. Eur Heart J 2014;35:753-757.
2. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns R-J, Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, Mc Clean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel Hebert K, Rapoza R, Ormiston JA. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold:a multi-imaging modality study at 6, 12, 24 and 36 months. Euro Intervention 2014;in press.
3. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stentstoprevent occlusionandrestenosisaftertransluminalangioplasty. NEngl JMed 1987;316:701-706.
4. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
5. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362: 1663-1674.
6. Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Juni P. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomized non-inferiority trial. Lancet 2011;378:1940-1948.
7. Iqbal J, Sumaya W, Tatman V, Parviz Y, Morton AC, Grech ED, Campbell S, Storey RF, Gunn J. Incidence and predictors of stent thrombosis: a single-centre study of 5, 833 consecutive patients undergoing coronary artery stenting. Euro Intervention 2013;9: 62-69.
8. Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K, Gao R, Bode C, Greenwood JP, Boersma E, Vranckx P, Mc Fadden E, Serruys PW, O'Neil WW, Jorissen B, Van Leeuwen F, Steg PG; PROTECT Steering Committee and Investigators. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 2012;380:1396-1405.
9. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabatè M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-1402.
10. Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Jüni P, Schömig A, Windecker S, Kastrati A. Biodegradable polymer drug-eluting stents reducethe riskofstent thrombosisat4yearsinpatientsundergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012;33:1214-1222.
11. Haude M, Erbel R, Erne P, Verheye S, Degen H, Böse D, Vermeersch P, Wijnbergen I, Weissman N, Prati F, Waksman R, Koolen J. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet 2013;381:836-844.
12. Kocka V, Malý M, Budeśinský T, Lisa L, Prodanov P, Tousek P, Jarkovský J, Widimský P. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'PRAGUE 19'. Eur Heart J 2014;35:787-794.
13. Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y, Nauta ST, Ishibashi Y, Lenzen MJ, Ligthart J, Schultz C, Regar E, de Jaegere PP, Serruys PW, Zijlstra F, van Geuns RJ. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction. BVS STEMI FIRST Study. Eur Heart J 2014;35:777-786.
14. Kajiya T, Liang M, Sharma RK, Lee CH, Chan MY, Tay E, Chan KH, Tan HC, Low AF. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). Euro Intervention 2013;9: 501-504.
15. Gori T, Schulz E, Hink U, Wenzel P, Post F, Jabs A, Münzel T. Early outcome after im-plantationof Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. Euro Intervention 2013;pii: 20130825-02. [Epub ahead of print]
16. Dudek D, Rzeszutko L, Lekston A, Zmudka K, Gil R, Dobrzycki S, Kleinrok A, Witkowsi A, Ciecwierz D, Lesiak M, Ochala A, Wojakoswki W, Przewlocki T, Gasior M, Grajek S, Zasada W, Depukat R, Partyka L. Bioserorbable vascular scaffolds in patients with acute coronary syndrome. The multicenter registry in Poland (POLAR ACS). Euro PCR 2013 (oral presentation).
17. Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, Costa JR Jr, Chamie D, Abizaid AS, Pinto I, Morrison L, Toyloy S, Bhat V, Yan J, Abizaid A. A next-generation bioresorbable coronary scaffold system-from bench to first clinical evaluation: six-and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv 2013;in press:doi:10. 1016/j. jcin. 2013. 07. 007